How Should Awareness of Ototoxicity Change the Way Medicine is Practiced?

P.K. Das-Purkayastha; J.A. Rutka

doi:10.1055/s-0031-1286618

Seminars in Hearing, Table of Contents

Semin Hear 2011; 32(3): 236-247
DOI: 10.1055/s-0031-1286618

How Should Awareness of Ototoxicity Change the Way Medicine is Practiced?

P.K. Das-Purkayastha¹ , J.A. Rutka²

¹Neurotology Clinical Fellow, University of Toronto, Toronto, Ontario, Canada
²Department of Otolaryngology, University of Toronto, Toronto, Ontario, Canada

Abstract

ABSTRACT

Ototoxicity is a topic relevant not only to otolaryngologists and audiologists, but also to any physician who prescribes medications for severely unwell or malignant conditions. Many of the drugs required to treat these conditions will possess side effects that have the potential to damage the inner ear thus causing severe morbidity. Unfortunately side effects that can profoundly affect hearing and balance are not always considered when prescribing potentially ototoxic medications. Regrettably, these problems often go unnoticed until there is severe deafness or an irreversible vestibular loss. This article aims to identify the potential controversies with regards to prescribing ototoxic medications, and discusses ways that a physician may use monitoring to alter their practice.

KEYWORDS

Ototoxicity - vestibulotoxicity - cochleotoxic - monitoring - genetic susceptibility

Full Text

References

REFERENCES

1 Council G M. Good practice in prescribing medicines—guidance for doctors. 2008. Available at: http://www.gmc-uk.org/static/documents/content/Good_Practice_in_Prescribing_Medicines_0911.pdf Accessed February, 2010
2 CPSO .Prescribing Practices. 2005. Available at: http://www.cpso.on.ca/policies/policies/default.aspx?ID=1848 Accessed July, 2010
3 Seligmann H, Podoshin L, Ben-David J, Fradis M, Goldsher M. Drug-induced tinnitus and other hearing disorders. Drug Saf. 1996; 14 198-212
4 Forge A, Schacht J. Aminoglycoside antibiotics. Audiol Neurootol. 2000; 5 3-22
5 Moore R D, Smith C R, Lietman P S. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis. 1984; 149 23-30
6 Neu H C, Bendush C L. Ototoxicity of tobramycin: a clinical overview. J Infect Dis. 1976; 134 (Suppl) S206-S218
7 Borradori C, Fawer C L, Buclin T, Calame A. Risk factors of sensorineural hearing loss in preterm infants. Biol Neonate. 1997; 71 1-10
8 Weatherly R A, Owens J J, Catlin F I, Mahoney D H. cis-platinum ototoxicity in children. Laryngoscope. 1991; 101 917-924
9 Yorgason J G, Fayad J N, Kalinec F. Understanding drug ototoxicity: molecular insights for prevention and clinical management. Expert Opin Drug Saf. 2006; 5 383-399
10 Brummett R E. Ototoxicity resulting from the combined administration of potent diuretics and other agents. Scand Audiol Suppl. 1981; 14 (Suppl) 215-224
11 Tran Ba Huy P, Manuel C, Meulemans A, Sterkers O, Wassef M, Amiel C. Ethacrynic acid facilitates gentamicin entry into endolymph of the rat. Hear Res. 1983; 11 191-202
12 Conlon B J, McSwain S D, Smith D W. Topical gentamicin and ethacrynic acid: effects on cochlear function. Laryngoscope. 1998; 108 1087-1089
13 Munckhof W J, Grayson M L, Turnidge J D. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother. 1996; 37 645-663
14 Hatala R, Dinh T, Cook D J. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med. 1996; 124 717-725
15 Bailey T C, Little J R, Littenberg B, Reichley R M, Dunagan W C. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997; 24 786-795
16 Ali M Z, Goetz M B. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997; 24 796-809
17 Barza M, Ioannidis J P, Cappelleri J C, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ. 1996; 312 338-345
18 Ferriols-Lisart R, Alós-Almiñana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharm. 1996; 53 1141-1150
19 Galløe A M, Graudal N, Christensen H R, Kampmann J P. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol. 1995; 48 39-43
20 Tran Ba Huy P, Bernard P, Schacht J. Kinetics of gentamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs. J Clin Invest. 1986; 77 1492-1500
21 Becvarovski Z, Michaelides E M, Kartush J M, Bojrab D I, LaRouere M J. Rapid elevation of gentamicin levels in the human labyrinth following intravenous administration. Laryngoscope. 2002; 112 (7 Pt 1) 1163-1165
22 Knutson J F, Murray K T, Husarek S et al.. Psychological change over 54 months of cochlear implant use. Ear Hear. 1998; 19 191-201
23 Hugues F C, Laccourreye A, Lasserre M H, Toupet M. Cochlear toxicity of erythromycin in elderly patients. Therapie. 1984; 39 591-594
24 Kotecha B, Richardson G P. Ototoxicity in vitro: effects of neomycin, gentamicin, dihydrostreptomycin, amikacin, spectinomycin, neamine, spermine and poly-L-lysine. Hear Res. 1994; 73 173-184
25 Richardson G P, Russell I J. Cochlear cultures as a model system for studying aminoglycoside induced ototoxicity. Hear Res. 1991; 53 293-311
26 McGhan L J, Merchant S N. Erythromycin ototoxicity. Otol Neurotol. 2003; 24 701-702
27 Swanson D J, Sung R J, Fine M J, Orloff J J, Chu S Y, Yu V L. Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am J Med. 1992; 92 61-68
28 Tange R A, Dreschler W A, Claessen F A, Perenboom R M. Ototoxic reactions of quinine in healthy persons and patients with Plasmodium falciparum infection. Auris Nasus Larynx. 1997; 24 131-136
29 Puel J L, Bobbin R P, Fallon M. Salicylate, mefenamate, meclofenamate, and quinine on cochlear potentials. Otolaryngol Head Neck Surg. 1990; 102 66-73
30 Karlsson K K, Flock A. Quinine causes isolated outer hair cells to change length. Neurosci Lett. 1990; 116 101-105
31 Zheng J, Ren T, Parthasarathi A, Nuttall A L. Quinine-induced alterations of electrically evoked otoacoustic emissions and cochlear potentials in guinea pigs. Hear Res. 2001; 154 124-134
32 Dieler R, Shehata-Dieler W E, Brownell W E. Concomitant salicylate-induced alterations of outer hair cell subsurface cisternae and electromotility. J Neurocytol. 1991; 20 637-653
33 Cazals Y. Auditory sensori-neural alterations induced by salicylate. Prog Neurobiol. 2000; 62 583-631
34 Peng B G, Chen S, Lin X. Aspirin selectively augmented N-methyl-D-aspartate types of glutamate responses in cultured spiral ganglion neurons of mice. Neurosci Lett. 2003; 343 21-24
35 Ding D, McFadden S L, Woo J M, Salvi R J. Ethacrynic acid rapidly and selectively abolishes blood flow in vessels supplying the lateral wall of the cochlea. Hear Res. 2002; 173 1-9
36 Hinojosa R, Riggs L C, Strauss M, Matz G J. Temporal bone histopathology of cisplatin ototoxicity. Am J Otol. 1995; 16 731-740
37 McAlpine D, Johnstone B M. The ototoxic mechanism of cisplatin. Hear Res. 1990; 47 191-203
38 Wake M, Takeno S, Ibrahim D, Harrison R, Mount R. Carboplatin ototoxicity: an animal model. J Laryngol Otol. 1993; 107 585-589
39 Takeno S, Harrison R V, Ibrahim D, Wake M, Mount R J. Cochlear function after selective inner hair cell degeneration induced by carboplatin. Hear Res. 1994; 75 93-102
40 Wake M, Takeno S, Ibrahim D, Harrison R. Selective inner hair cell ototoxicity induced by carboplatin. Laryngoscope. 1994; 104 488-493
41 Takeno S, Harrison R V, Mount R J, Wake M, Harada Y. Induction of selective inner hair cell damage by carboplatin. Scanning Microsc. 1994; 8 97-106
42 Konigsmark B W, Gorlin R J. Genetic and Metabolic Deafness. Philadelphia, PA: Saunders; 1976
43 Tsuiki T, Murai S. Familial incidence of streptomycin hearing loss and hereditary weakness of the cochlea. Audiology. 1971; 10 315-322
44 Hu D N, Qui W Q, Wu B T et al.. Genetic aspects of antibiotic induced deafness: mitochondrial inheritance. J Med Genet. 1991; 28 79-83
45 Fischel-Ghodsian N. Genetic factors in aminoglycoside toxicity. Ann N Y Acad Sci. 1999; 884 99-109
46 Braverman I, Jaber L, Levi H et al.. Audiovestibular findings in patients with deafness caused by a mitochondrial susceptibility mutation and precipitated by an inherited nuclear mutation or aminoglycosides. Arch Otolaryngol Head Neck Surg. 1996; 122 1001-1004
47 Roth S M, Williams S M, Jiang L, Menon K S, Jeka J J. Susceptibility genes for gentamicin-induced vestibular dysfunction. J Vestib Res. 2008; 18 59-68
48 Li Y, Womer R B, Silber J H. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer. 2004; 40 2445-2451
49 Coradini P P, Cigana L, Selistre S G, Rosito L S, Brunetto A L. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol. 2007; 29 355-360
50 Knight K R, Kraemer D F, Neuwelt E A. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005; 23 8588-8596
51 Kushner B H, Budnick A, Kramer K, Modak S, Cheung N K. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer. 2006; 107 417-422
52 Blakley B W, Gupta A K, Myers S F, Schwan S. Risk factors for ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg. 1994; 120 541-546
53 Bess F H, Dodd-Murphy J, Parker R A. Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status. Ear Hear. 1998; 19 339-354
54 Ross C J, Katzov-Eckert H, Dubé M P CPNDS Consortium et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet. 2009; 41 1345-1349
55 Rourke T. Aminoglycoside ototoxicity: how practical is this genetic screening test?. BMJ. 2007; 335 952
56 Campbell K CM. Audiologic monitoring for ototoxicity. In: Roland P S, Rutka J A, eds. Ototoxicity. Hamilton, Ontario, Canada: BC Decker Inc.; 2004
57 Burger T, Spahn C, Richter B, Eissele S, Löhle E, Bengel J. Psychic stress and quality of life in parents during decisive phases in the therapy of their hearing-impaired children. Ear Hear. 2006; 27 313-320
58 Mulrow C D, Aguilar C, Endicott J E et al.. Quality-of-life changes and hearing impairment. A randomized trial. Ann Intern Med. 1990; 113 188-194
59 Hallberg L R, Ringdahl A. Living with cochlear implants: experiences of 17 adult patients in Sweden. Int J Audiol. 2004; 43 115-121
60 Arlinger S. Negative consequences of uncorrected hearing loss—a review. Int J Audiol. 2003; 42 (Suppl 2) S17-S20
61 Eisenberg L S. Use of the cochlear implant by the prelingually deaf. Ann Otol Rhinol Laryngol Suppl. 1982; 91 (2 Pt 3) 62-66
62 Fellinger J, Holzinger D, Dobner U et al.. Mental distress and quality of life in a deaf population. Soc Psychiatry Psychiatr Epidemiol. 2005; 40 737-742
63 Spahn C, Burger T, Löschmann C, Richter B. Quality of life and psychological distress in parents of children with a cochlear implant. Cochlear Implants Int. 2004; 5 13-27
64 Hogan A, Hawthorne G, Kethel L et al.. Health-related quality-of-life outcomes from adult cochlear implantation: a cross-sectional survey. Cochlear Implants Int. 2001; 2 115-128
65 Wake M, Hughes E K, Collins C M, Poulakis Z. Parent-reported health-related quality of life in children with congenital hearing loss: a population study. Ambul Pediatr. 2004; 4 411-417
66 Jerger J F, Carhart R, Tillman T W, Peterson J L. Some relations between normal hearing for pure tones and for speech. J Speech Hear Res. 1959; 2 126-140
67 American Speech-Language-Hearing Association . Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA. 1994; 36 (Suppl 12) 11-19
68 Campbell K. Ototoxicity: understanding oxidative mechanisms. J Am Acad Audiol. 2003; 14 121-123
69 Fausti S A, Larson V D, Noffsinger D, Wilson R H, Phillips D S, Fowler C G. High-frequency audiometric monitoring strategies for early detection of ototoxicity. Ear Hear. 1994; 15 232-239
70 Ress B D, Sridhar K S, Balkany T J, Waxman G M, Stagner B B, Lonsbury-Martin B L. Effects of cis-platinum chemotherapy on otoacoustic emissions: the development of an objective screening protocol. Third place—Resident Clinical Science Award 1998. Otolaryngol Head Neck Surg. 1999; 121 693-701
71 Sha S H, Taylor R, Forge A, Schacht J. Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals. Hear Res. 2001; 155 1-8
72 Wright D E, Drouin P. Cisplatin-induced myasthenic syndrome. Clin Pharm. 1982; 1 76-78
73 Gorga M P, Neely S T, Bergman B et al.. Otoacoustic emissions from normal-hearing and hearing-impaired subjects: distortion product responses. J Acoust Soc Am. 1993; 93 (4 Pt 1) 2050-2060
74 Rybak L P, Whitworth C A. Ototoxicity: therapeutic opportunities. Drug Discov Today. 2005; 10 1313-1321
75 Beattie R C, Kenworthy O T, Luna C A. Immediate and short-term reliability of distortion-product otoacoustic emissions. Int J Audiol. 2003; 42 348-354
76 Knight K R, Kraemer D F, Winter C, Neuwelt E A. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol. 2007; 25 1190-1195
77 Halmagyi G M, Curthoys I S. A clinical sign of canal paresis. Arch Neurol. 1988; 45 737-739
78 Halmagyi M, Curthoys I S, Aw S T. The human vestibulo-ocular reflex after unilateral vestibular differentiation. The results of high acceleration impulsive testing. In: Sharpe J, Barber H O, eds. The Vestibulo-Ocular Reflex and Vertigo. New York, NY: Raven Press; 1993: 45-54
79 Chambers B R, Mai M, Barber H O. Bilateral vestibular loss, oscillopsia, and the cervico-ocular reflex. Otolaryngol Head Neck Surg. 1985; 93 403-407
80 Coats A C, Smith S Y. Body position and the intensity of caloric nystagmus. Acta Otolaryngol. 1967; 63 515-532
81 Fee Jr W E. Aminoglycoside ototoxicity in the human. Laryngoscope. 1980; 90 (10 Pt 2, Suppl 24) 1-19
82 Tomlinson R D, Saunders G E, Schwarz D W. Analysis of human vestibulo-ocular reflex during active head movements. Acta Otolaryngol. 1980; 90 184-190
83 Van De Water T R, Rybak L P. Ototoxic damage to hearing: Otoprotective Therapies. In: Roland P S, Rutka J A, eds. Ototoxicity. Hamilton, Ontario, Canada: BC Decker Inc.; 2004
84 Gallagher T H, Waterman A D, Ebers A G, Fraser V J, Levinson W. Patients' and physicians' attitudes regarding the disclosure of medical errors. JAMA. 2003; 289 1001-1007
85 Hébert P C, Levin A V, Robertson G. Bioethics for clinicians: 23. Disclosure of medical error. CMAJ. 2001; 164 509-513
86 Song B B, Anderson D J, Schacht J. Protection from gentamicin ototoxicity by iron chelators in guinea pig in vivo. J Pharmacol Exp Ther. 1997; 282 369-377
87 Schacht J. Antioxidant therapy attenuates aminoglycoside-induced hearing loss. Ann N Y Acad Sci. 1999; 884 125-130
88 Chen Y, Huang W G, Zha D J et al.. Aspirin attenuates gentamicin ototoxicity: from the laboratory to the clinic. Hear Res. 2007; 226 178-182
89 Fouladi M, Chintagumpala M, Ashley D et al.. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol. 2008; 26 3749-3755

J.A. RutkaM.D. F.R.C.S.C.

Toronto General Hospital, Eaton Wing 8N-873

200 Elizabeth Street, Toronto, ON M5G 2C4

Email: John.Rutka@uhn.on.ca